Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Radiation Oncology
•
Hematology
What is the role of palliative radiotherapy in hemophagocytic lymphohistiocytosis (HLH) causing painful splenomegaly?
If there is a role, which dose would you recommend?
Related Questions
Would you offer XRT as bridging for all patients with limited pre CAR-T disease or as consolidation for only those with residual PET-avidity on day+30 post CAR-T?
How would you manage a pre-menopausal woman with extranodal marginal zone lymphoma confined to the bladder wall?
Would you offer consolidative scrotal RT for patients with bilateral testicular lymphoma involvement s/p bilateral orchiectomy and chemotherapy?
What hypofractionated radiotherapy dose regimen is acceptable for plasmacytoma?
What is your approach to cancer patients who inquire about alternative or complementary treatments?
How will you manage a patient with symptomatic secondary CNS involvement from DLBCL not eligible for HD-MTX?
Which patients with relapsed/refractory NHL are appropriate for pre-CAR-T bridging radiation therapy?
Does the use of A+AVD versus ABVD affect your decision for consolidation RT for bulky Hodgkin lymphoma?
For patients with solitary plasmacytoma of the ureter undergoing definitive XRT (40-50 Gy), what dose constraint do you use for the ureter?
Is there an optimal bridging radiation dose for aggressive B-cell NHL undergoing CAR T-cell therapy?